The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
In December 2025, Castle Biosciences reported Nature Communications data from the largest prospective, multicenter uveal melanoma study showing that combining its DecisionDx-UM test with PRAME gene ...
The Global Gene Expression Market is estimated to be valued at USD 16.56 Bn in 2025 and is expected to reach USD 23.61 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2025 to ...
TripletDGC links disease genes→cell types→diseases via eQTL-scRNA integration, exposing sparse but critical cell drivers and potential comorbidity ...
BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...
DecisionDx-Melanoma demonstrates robust clinical utility and validated performance, supported by high-quality (SORT A) evidence showing accurate and consistent prognostic information for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback